Buy Like Buffett
Watchlist

Flagship explainer

How AGIOS PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$54M · 100%Cost of revenue$6.3M · 12%Gross profit$47.7M · 88%Operating income−$472M · −874%Income before tax−$414M · −766%Income tax−$1M · −2%Net income−$413M · −764%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$54M100%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
Cost of revenue$6.3M12%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
$47.7M88%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
−$472M−874%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
Income before tax−$414M−766%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
Income tax−$1M−2%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
−$413M−764%
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001439222-26-000025 · filed Feb 12, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full AGIOS PHARMACEUTICALS, INC. analysis at Buy Like Buffett